Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Xenical Patient Retention Program Is Key To Sales Growth

Executive Summary

Roche has set up a Xenical patient retention program in the U.S. in a continuing effort to improve the obesity drug's sales record.

You may also be interested in...



Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording

Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim

Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording

Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim

Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication

Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.

Related Content

UsernamePublicRestriction

Register

PS037444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel